NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Sol-Gel Technologies Ltd. SLGL
11 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 3.8M
Revenue, FY2025 · full 11-year series below
Revenue $M
Net income $M
FY2025 · Revenue 3.8 · Net income -6.1
Compound annual growth
Revenue compounded at −15.2% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−161 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -198.4% · Net -161.2%
ROE
FY2025 · ROE -23.7%
Each USD of equity lost 24 cents this year.
The 11-year record
11 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −2.19 | −3.79 | −10.01 | −0.65 | 0.14 | −1.30 | −1.26 | 1.80 | 5.02 | 3.30 | 1.53 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −23.7 | −31.4 | −67.4 | −30.5 | 6.1 | −56.7 | −42.3 | −574.5 | · | · | · |
| Shares out B | 0.00 | 0.00 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 42 reconciliationsAUDITED
Reconciled in 11 of 19 fiscal years. 34 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code L3
Fiscal year endsDecember 31
Data on record since2015